Inhaled budesonide for chronic wheezing under 18 months of age.

Author: EverardM L, MilnerA D, NobleV, RugginsN R

Paper Details 
Original Abstract of the Article :
The role of budesonide in controlling chest symptoms in infants was assessed. It was administered from a metered dose inhaler into a large volume spacer (Nebuhaler) with attached Laerdal mask. Twenty nine infants were recruited into a double blind crossover trial. Five defaulted. The remaining 24 (m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1136/adc.67.3.285

データ提供:米国国立医学図書館(NLM)

Budesonide for Wheezing Infants: A Double-Blind Crossover Trial

Pediatric medicine is a fascinating field, full of unique challenges. One such challenge is managing chronic wheezing in infants. This study, published in the journal Archives of Disease in Childhood, investigated the effectiveness of budesonide, a corticosteroid, in treating wheezing in infants under 18 months of age. The researchers conducted a double-blind crossover trial with 24 infants, comparing budesonide to placebo. They assessed the infants' tolerance to the medication, any adverse effects, treatment failures, parental opinions, and symptom severity. The results were promising! The study found that budesonide, administered via a metered dose inhaler and spacer, was well-tolerated by the infants, and that it effectively reduced wheezing symptoms. Parents of infants who completed the full treatment period generally preferred budesonide over placebo. This research, like a cool desert breeze, provides hope for managing wheezing in young children.

Promising Results for Wheezing Infants

This study, a beacon of hope in the desert of childhood wheezing, indicates that budesonide delivered in this manner can be a valuable treatment option for infants who need prophylaxis for their wheezing. This finding could significantly improve the quality of life for infants and their families, allowing them to breathe easy and enjoy the world around them.

A Breath of Fresh Air for Wheezing Infants

The use of budesonide, a corticosteroid, in wheezing infants is like finding an oasis in the desert! It provides relief from the harsh symptoms of wheezing, improving the infants' overall health and well-being. It's important to note that while these results are encouraging, further research is necessary to understand the long-term effects of budesonide on infants. Parents should always consult with their pediatrician before starting any new treatment for their children.

Dr.Camel's Conclusion

The findings of this study suggest that budesonide given in this way is an effective treatment for infants who may need prophylaxis for their wheezing. It's a beacon of hope in the vast desert of childhood respiratory illnesses. This study, like a cool, refreshing breeze, provides hope for families dealing with wheezing in their infants.

Date :
  1. Date Completed 1992-05-29
  2. Date Revised 2019-05-01
Further Info :

Pubmed ID

1575550

DOI: Digital Object Identifier

10.1136/adc.67.3.285

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.